{"id":"W2789531094","doi":"10.1158/1538-7445.sabcs17-p5-20-06","title":"Abstract P5-20-06: Phase 1 dose escalation with ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-high breast cancer (BC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Lapatinib; Pertuzumab; Trastuzumab; Internal medicine; Cancer; Oncology; Metastatic breast cancer; Breast cancer; Gastroenterology; Nuclear medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005577097,0.0007819277,0.0005869625,0.0003386458,0.0002380689,0.000430715,0.0005055975,0.0005406914,0.003979825],"category_scores_gemma":[0.0003784506,0.0002353594,0.0004625643,0.0002308723,0.00035127,0.0003947193,0.0003158591,0.001465611,0.0007742676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005806789,"about_ca_system_score_gemma":0.0006883423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006900257,"about_ca_topic_score_gemma":0.001271077,"domain_scores_codex":[0.9998602,0.00004837949,0.00001003135,0.00002726654,0.00001793365,0.00003621944],"domain_scores_gemma":[0.9998381,0.00001914175,0.00003289989,0.00001074783,0.00001639267,0.00008260577],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2695017,0.08078194,0.01151212,0.001143268,0.0007657978,0.0006842299,0.0006087025,0.007353278,0.248212,0.0007054725,0.009780168,0.3689513],"study_design_scores_gemma":[0.1605586,0.7654162,0.02705071,0.00005379036,0.0003376481,0.0008797941,0.00009157039,0.003030504,0.03344481,0.0003307885,0.008772559,0.0000331026],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935183,0.0007620968,0.0007766784,0.0001673958,0.00002753265,0.001995243,0.0006093752,0.0001076834,0.002035633],"genre_scores_gemma":[0.9899917,0.0006811926,0.002296843,0.0003740021,0.00004530056,0.001618701,0.001584692,0.00002829467,0.003379238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003979825,"threshold_uncertainty_score":0.01331389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04813735197770432,"score_gpt":0.4099717730259086,"score_spread":0.3618344210482043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}